Genetic Variations in Multiple Drug Action Pathways and Survival in Advanced Stage Non-small Cell Lung Cancer Treated with Chemotherapy

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2011 Jun 4

PMID 21636554

Citations 16

Authors

Yafei Li

Zhifu Sun

Julie M Cunningham

Marie C Aubry

Jason A Wampfler

Gary A Croghan

Cassandra Johnson

Danli Wu

Jeremiah A Aakre

Julian Molina

Liewei Wang

V Shane Pankratz

Ping Yang

Affiliations

Soon will be listed here.

Abstract

Purpose: Variations in genes related to biological activity of anticancer drugs could influence treatment responses and lung cancer prognosis. Genetic variants in four biological pathways, that is, glutathione metabolism, DNA repair, cell cycle, and epidermal growth factor receptor (EGFR), were systematically investigated to examine their association with survival in advanced stage non-small cell lung cancer (NSCLC) treated with chemotherapy.

Experimental Design: A total of 894 tagging single-nucleotide polymorphisms (SNP) in 70 genes from the four pathways were genotyped and analyzed in a 1,076-patient cohort. Association with overall survival was analyzed at SNP and whole-gene levels within all patients and major chemotherapy agent combination groups.

Results: A poorer overall survival was observed in patients with genetic variations in GSS (glutathione pathway) and MAP3K1 (EGFR pathway; HR = 1.45; 95% CI = 1.20-1.77 and HR = 1.25; 95% CI = 1.05-1.50, respectively). In the stratified analysis on patients receiving platinum plus taxane treatment, we observed a hazardous effect on overall survival by the MAP3K1 variant (HR = 1.38; 95% CI = 1.11-1.72) and a protective effect by RAF1 (HR = 0.64; 95% CI = 0.50-0.82) in the EGFR pathway. In patients receiving platinum plus gemcitabine treatment, RAF1 and GPX5 (glutathione pathway) genetic variations showed protective effects on survival (HR = 0.54; 95% CI = 0.38-0.77; HR = 0.67; 95% CI = 0.52-0.85, respectively); in contrast, NRAS (EGFR pathway) and GPX7 (glutathione pathway) variations showed hazardous effects on overall survival (HR = 1.91; 95% CI = 1.30-2.80; HR = 1.83; 95% CI = 1.27-2.63, respectively). All genes that harbored these significant SNPs remained significant by whole-gene analysis.

Conclusion: Common genetic variations in genes of EGFR and glutathione pathways may be associated with overall survival among patients with advanced stage NSCLC treated with platinum, taxane, and/or gemicitabine combinations.

Citing Articles

Primary intracranial sarcomas: a clinicopathological investigation.

Cai Y, Liu J, Xu J, He Y, Zhang H, Tian S Front Oncol. 2023; 13:1195467.

PMID: 37361584 PMC: 10288519. DOI: 10.3389/fonc.2023.1195467.

SYVN1/GPX5 axis affects ischemia/reperfusion induced apoptosis of AC16 cells by regulating ROS generation.

Zhang J, Jiang S, Lu C, Pang J, Xu H, Yang F Am J Transl Res. 2021; 13(5):4055-4067.

PMID: 34149998 PMC: 8205806.

Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC-guided dosing in nonsmall cell lung cancer.

Ma Y, Zhao X, Chen X, Huang X, Lin Q, Lin Y Clin Transl Med. 2021; 11(4):e354.

PMID: 33931979 PMC: 8021539. DOI: 10.1002/ctm2.354.

MAP3K1 rs889312 genotypes influence survival outcomes of Chinese gastric cancer patients who received adjuvant chemotherapy based on platinum and fluorouracil regimes.

Yang J, Zheng W, Xu Z, Chen J Onco Targets Ther. 2019; 12:6843-6855.

PMID: 31686841 PMC: 6709816. DOI: 10.2147/OTT.S205438.

Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.

Xie D, Allen M, Marks R, Jiang G, Sun Z, Nichols F Eur J Cardiothorac Surg. 2018; 53(6):1214-1222.

PMID: 29293957 PMC: 5961359. DOI: 10.1093/ejcts/ezx462.

References

Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg D, Wain J . Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004; 10(15):4939-43. DOI: 10.1158/1078-0432.CCR-04-0247. View

Nicholson R, Gee J, Harper M . EGFR and cancer prognosis. Eur J Cancer. 2001; 37 Suppl 4:S9-15. DOI: 10.1016/s0959-8049(01)00231-3. View

Yang P, Ebbert J, Sun Z, Weinshilboum R . Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol. 2006; 24(11):1761-9. DOI: 10.1200/JCO.2005.02.7110. View

Yang P, Sun Z, Krowka M, Aubry M, Bamlet W, Wampfler J . Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med. 2008; 168(10):1097-103. PMC: 2562773. DOI: 10.1001/archinte.168.10.1097. View

Zhang W, Stoehlmacher J, Park D, Yang D, Borchard E, Gil J . Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2005; 5(2):124-31. DOI: 10.3816/ccc.2005.n.025. View

Halliwell B . Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res. 1999; 31(4):261-72. DOI: 10.1080/10715769900300841. View

Walker S . Updates in non-small cell lung cancer. Clin J Oncol Nurs. 2008; 12(4):587-96. DOI: 10.1188/08.CJON.587-596. View

Zhao J, Kim J, Reed E, Li Q . Molecular mechanism of antitumor activity of taxanes in lung cancer (Review). Int J Oncol. 2005; 27(1):247-56. View

Udler M, Maia A, Cebrian A, Brown C, Greenberg D, Shah M . Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol. 2007; 25(21):3015-23. DOI: 10.1200/JCO.2006.10.0099. View

10.

Sun Z, Chen J, Aakre J, Marks R, Garces Y, Jiang R . Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol. 2010; 21(10):2011-2016. PMC: 2946864. DOI: 10.1093/annonc/mdq212. View

11.

Kerkhoff E, Rapp U . Cell cycle targets of Ras/Raf signalling. Oncogene. 1998; 17(11 Reviews):1457-62. DOI: 10.1038/sj.onc.1202185. View

12.

Beeram M, Patnaik A, Rowinsky E . Regulation of c-Raf-1: therapeutic implications. Clin Adv Hematol Oncol. 2005; 1(8):476-81. View

13.

Karimianpour N, Mousavi-Shafaei P, Ziaee A, Akbari M, Pourmand G, Abedi A . Mutations of RAS gene family in specimens of bladder cancer. Urol J. 2008; 5(4):237-42. View

14.

Carlson C, Eberle M, Kruglyak L, Nickerson D . Mapping complex disease loci in whole-genome association studies. Nature. 2004; 429(6990):446-52. DOI: 10.1038/nature02623. View

15.

Stanton Jr V, Cooper G . Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol Cell Biol. 1987; 7(3):1171-9. PMC: 365190. DOI: 10.1128/mcb.7.3.1171-1179.1987. View

16.

Cornwell M, Smith D . A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem. 1993; 268(21):15347-50. View

17.

Kerkhoff E, Fedorov L, Siefken R, Walter A, Papadopoulos T, Rapp U . Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ. 2000; 11(4):185-90. View

18.

Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M . Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004; 15(8):1194-203. DOI: 10.1093/annonc/mdh319. View

19.

Gligorov J, Lotz J . Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004; 9 Suppl 2:3-8. DOI: 10.1634/theoncologist.9-suppl_2-3. View

20.

Yang P, Bamlet W, Sun Z, Ebbert J, Aubry M, Krowka M . Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest. 2005; 128(1):445-52. DOI: 10.1378/chest.128.1.445. View